在急性心力衰竭患者中,静脉流量的变化和从替代疗法中释放
Cardiorenal medicine
|June 10, 2025
概括
静脉流量 (RVF) 的改善表明,在急性心力衰竭 (AHF) 患者中,成功中止了替代疗法 (RRT). 连续的RVF评估可以通过监测心功能恢复来指导RRT管理.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 医疗成像医学成像
背景情况:
- 急性心力衰竭 (AHF) 患者往往需要脏替代疗法 (RRT).
- 在AHF中成功停止RRT的预测因素尚未确定.
- 心脏病综合征的动态需要进一步调查.
研究的目的:
- 调查多普勒衍生的静脉流 (RVF) 波形改善是否预测AHF中成功的RRT中止.
- 探索RVF标记物与RRT解放之间的关联.
- 评估RVF在监测心功能恢复中的作用.
主要方法:
- 对前性队列研究的后期分析.
- 包括接受急性RRT的AHF患者.
- 在RRT启动之前和之后进行连续脏多普勒评估.
- 后勤回归分析RVF标记 (IRVF,RVSI),心声回声数据和RRT停止之间的关联.
主要成果:
- 19% (10/53) 的患者成功停止了RRT.
- 内静脉流量 (IRVF) 和静脉静止指数 (RVSI) 的严重程度增加与RRT停止有负相关性.
- 改善的右心室功能标志物,如TAPSE/sPAP比率,与更高的RRT停药几率相关.
结论:
- 静脉流 (RVF) 的改善与AHF中成功停止RRT有关.
- 序列RVF评估提供了一种非侵入性方法来追踪心脏脏综合征和脏恢复.
- 需要进一步研究更大的队列和优化的多普勒评估,以指导AHF的RRT管理.
相关概念视频
01:30Continuous Renal Replacement Therapy
2
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2
01:22Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
01:22Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
01:30Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
01:29Heart Failure II: Pathophysiology
3
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3